Enhanced Hydrocortisone Sodium Phosphate Formulation for Topical Application

The inventive concept relates to an optimized pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol, designed to improve skin penetration, stability, and efficacy for treating allergic reactions and inflammatory skin conditions.

The original patent disclosed an aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol. However, this formulation has limitations, such as limited skin penetration, potential instability, and variable efficacy. The new inventive concept addresses these limitations by introducing novel enhancements to the formulation, including optimized pH-adjusted buffer systems, novel preservative combinations, and improved bioavailability.

The inventive concept comprises a pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol, wherein the formulation is optimized for enhanced skin penetration through the use of a pH-adjusted buffer system, stabilized with a novel combination of preservatives, and designed for rapid dissolution to improve bioavailability. The formulation can be administered topically using a device for simultaneous injection or a dual-chamber container for co-administration. The inventive concept also encompasses a method for treating allergic reactions and inflammatory skin conditions using the optimized formulation.

The new claims introduce novel and non-obvious improvements to the original formulation, including the use of pH-adjusted buffer systems, novel preservative combinations, and optimized bioavailability. These enhancements provide a significant advance over the original patent, addressing the limitations of skin penetration, stability, and efficacy.

Alternative embodiments of the inventive concept may include varying the concentration of hydrocortisone sodium phosphate and monothioglycerol, using different preservative combinations, or incorporating additional ingredients to enhance skin penetration and efficacy. Variations of the device for topical application or the dual-chamber container may also be explored to improve user convenience and ease of use.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of allergic reactions and inflammatory skin conditions. The optimized formulation and novel administration methods may provide a competitive advantage in the market, offering improved efficacy, convenience, and patient outcomes.